868245-03-8

Basic information

• Product Name: 5-PIPERAZIN-1-YL-INDAN-1-ONE
• Synonyms: 5-PIPERAZIN-1-YL-INDAN-1-ONE;5-(Piperazin-1-yl)-2,3-dihydro-1H-inden-1-one
• CAS NO: 868245-03-8
• Molecular Formula: C13H16N2O
• Molecular Weight: 216.28
• Mol File: 868245-03-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 423.1°C at 760 mmHg
• Flash Point: 209.7°C
• Appearance: /
• Density: 1.179g/cm³
• Vapor Pressure: 2.29E-07mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-PIPERAZIN-1-YL-INDAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PIPERAZIN-1-YL-INDAN-1-ONE(868245-03-8)
• EPA Substance Registry System: 5-PIPERAZIN-1-YL-INDAN-1-ONE(868245-03-8)

Safety Data

• Hazardous Substances Data: 868245-03-8(Hazardous Substances Data)

Usage

General Description

5-PIPERAZIN-1-YL-INDAN-1-ONE is a chemical compound with the molecular formula C13H16N2O. It is a psychoactive drug that acts as a selective serotonin releasing agent and a dopamine reuptake inhibitor. The compound has been studied for its potential use in the treatment of depression, anxiety, and other mental health disorders. It has also been researched for its potential as a recreational drug, with reports of users experiencing euphoria, increased energy, and enhanced sensory perception. However, this compound has not been approved for medical use and is considered a controlled substance in many countries due to its potential for abuse and addiction. Further research is needed to fully understand the effects and safety of 5-PIPERAZIN-1-YL-INDAN-1-ONE.

InChI:InChI=1/C13H16N2O/c16-13-4-1-10-9-11(2-3-12(10)13)15-7-5-14-6-8-15/h2-3,9,14H,1,4-8H2

Upstream product

• 110-85-0 piperazine 
• 700-84-5 5-fluoro-1-indanone 

Relevant articles and documents

Structure-Based Optimization of Pyridoxal 5′-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis

The pyridoxal 5′-phosphate (PLP)-dependent transaminase BioA catalyzes the second step in the biosynthesis of biotin in Mycobacterium tuberculosis (Mtb) and is an essential enzyme for bacterial survival and persistence in vivo. A promising BioA inhibitor 6 containing an N-aryl, N′-benzoylpiperazine scaffold was previously identified by target-based whole-cell screening. Here, we explore the structure-activity relationships (SAR) through the design, synthesis, and biological evaluation of a systematic series of analogues of the original hit using a structure-based drug design strategy, which was enabled by cocrystallization of several analogues with BioA. To confirm target engagement and discern analogues with off-target activity, each compound was evaluated against wild-type (WT) Mtb in biotin-free and -containing medium as well as BioA under- and overexpressing Mtb strains. Conformationally constrained derivative 36 emerged as the most potent analogue with a KD of 76 nM against BioA and a minimum inhibitory concentration of 1.7 μM (0.6 μg/mL) against Mtb in biotin-free medium.

Synthesis of 2-[4-(imidazolin-2-ylideneamino)benzyl]-Indan-1-ones as novel potent prostacyclin antagonists

Prostacyclin is involved in many pathological conditions, such as sensitization of inflammation induced pain and isovolumetic distention. Therefore, antagonism of prostacyclin action may be useful in the alleviation of these conditions. In this study, nov

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.